<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The cardiovascular complications of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) remain the primary source of morbidity and mortality in affected patients </plain></SENT>
<SENT sid="1" pm="."><plain>Over the last decade, the underlying pathogenesis of these <z:hpo ids='HP_0001626'>cardiovascular abnormalities</z:hpo> has been the focus of much research </plain></SENT>
<SENT sid="2" pm="."><plain>Such research has shed light on the potential role of several novel medical therapies and their ability to prevent <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> progression </plain></SENT>
<SENT sid="3" pm="."><plain>This paper summarizes the research underlying new medical therapies and provides a review of the scientific foundation underlying <z:hpo ids='HP_0000001'>all</z:hpo> current medical therapies used for prevention of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, including <z:chebi fb="0" ids="35530">beta-adrenoceptor antagonists</z:chebi>, calcium channel <z:chebi fb="68" ids="48706">antagonists</z:chebi>, <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi>, and angiotensin receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
</text></document>